CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation (CRY)

CryoLife, Inc. CRY, an implantable biological medical device and cardiovascular tissue processing company, today announced the final results of its tender offer, including proration results, through its wholly owned subsidiary CL Falcon, Inc., for 49.9 percent of the outstanding shares of Cardiogenesis Corporation ("Cardiogenesis") CGCP.  The tender offer expired at 12:00 midnight, Eastern Time, at the end of the day on Monday, May 2, 2011.